Lynne Nardizzi, LICSW

Street Address

City, State, Zip

415-342-6717

support and integration for psychedelics, bad trips and spiritual crises and experiences

PSYCHOTHERAPY FOR ADOLESCENTS, CHildren AND ADULTS

Lynne Nardizzi, LICSW

Blog

Psychedelics and Self-Treatment

May 20, 2023 Lynne Nardizzi

This study investigated the patterns of use, self-reported outcomes and outcome predictors of psychedelic ‘self-treatment’ of mental health conditions or specific worries/concerns in life.

Positive changes were observed across all 17 outcome items, with the strongest benefits on items related to insight and mood.

Psilocybin and Lyme Disease?

May 19, 2023 Lynne Nardizzi

Psilocybin is both serotonergic and anti-inflammatory and therefore may offer significant therapeutic benefits to patients with mental illness secondary to autoimmune inflammation.

This study suggests that the role of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease and autoimmune encephalopathies warrants further study.

LSD, Psychosis and Healing

May 18, 2023 Lynne Nardizzi

This study explores the paradoxical relationship connecting key parameters of the psychotic experience, psychotherapy, and psychedelic experience.

The link between psychosis model and therapeutic model seems to lie in mystical experiences.

The results point to the importance of meaning attribution for the LSD psychosis model and indicate that psychedelic-assisted therapy might benefit from therapeutic suggestions fostering mystical experiences.

Ketamine for Adolescents?

May 17, 2023 Lynne Nardizzi

This ketamine study looks at four adolescent cases (aged 14–19), each with a variety of comorbid diagnoses including treatment-resistant depression, bipolar disorder, eating disorders, anxiety, panic, and trauma-related symptoms.

Their courses varied, but each had symptomatic and functional improvements, and the ketamine treatment was well-tolerated.

Integration for Ketamine

May 15, 2023 Lynne Nardizzi

Here’s a great article on what is integration and why it's important in ketamine therapy.

Psychedelics and Antidepressants

May 9, 2023 Lynne Nardizzi

Drug historian David Herzberg discusses the history of “mind medicines” like Prozac, and parallels between antidepressants and psychedelics.

Psychedelics and Bipolar Disorder

May 8, 2023 Lynne Nardizzi

Here’s a look at some research into the risks and potential benefits of psychedelics for bipolar disorder.

Spiritual Bypassing with Psychedelics

May 7, 2023 Lynne Nardizzi

Psychedelic Bypassing: The many ways the mind can excuse abuse, ignore the darker sides of ourselves, categorize the vast scale of emotions into little boxes of “good” and “bad,” and cast aside anything deemed “lesser than” — all in the pursuit of a more enlightened life.

Avoidance is mistaken for healing.

Brain Activity During Dying

May 6, 2023 Lynne Nardizzi

A new study hints at how consciousness can continue after the heart stops. A burst of brain activity during dying could explain life passing before your eyes.

An LSD Analogue and Therapeutic Potential

May 5, 2023 Lynne Nardizzi

An analogue of LSD (or 2-bromo-LSD) has been demonstrated to produce neuroplastic effects without producing tolerance, a head twitch response, or binding to 5HT2B receptors which is potentially linked to valvular heart disease.

Update on Oregon

May 4, 2023 Lynne Nardizzi

In 2020, Oregon was the first state in the U.S. to effectively legalize psilocybin, the hallucinogenic component of magic mushrooms, for therapeutic use.

It has shown to be effective in treating post-traumatic stress disorder, depression and end-of-life anxiety.

Since then, regulations and restrictions for psilocybin treatment have taken shape across the state with many rural counties opting out of providing any psilocybin-related services at all.